InflaRx Management

Management criteria checks 2/4

InflaRx's CEO is Niels Riedemann, appointed in Jan 2007, has a tenure of 17.33 years. directly owns 1.82% of the company’s shares, worth $1.46M. The average tenure of the management team and the board of directors is 3.4 years and 5 years respectively.

Key information

Niels Riedemann

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	17.3yrs
CEO ownership	1.8%
Management average tenure	3.4yrs
Board average tenure	5yrs

Recent management updates

Recent updates

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

Sep 29

InflaRx reports Q2 results

Aug 05

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Jul 26

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

Jul 16

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul 06

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

Jun 29

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Apr 01

Our First Look At InflaRx

Dec 29

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Dec 15

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 27

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

Aug 25

InflaRx initiates mid-stage vilobelimab skin cancer trial

Jun 08

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

May 01

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

Mar 02

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Jan 08

InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder

Jan 05

InflaRx reports Q3 results

Oct 29

CEO

Niels Riedemann (50 yo)

17.3yrs

Tenure

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Niels Riedemann	Co-Founder	17.3yrs	no data	1.82% € 1.5m
Renfeng Guo	Co-Founder	17.3yrs	no data	2.99% € 2.4m
Thomas Taapken	Chief Financial Officer	3.6yrs	no data	0.0059% € 4.8k
Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance	1.1yrs	no data	no data
Camilla Chong	Chief Medical Officer	less than a year	no data	no data
Jan Medina	Head of Investor Relations & VP	less than a year	no data	no data
Christian Schmid	VP and Head of Legal Affairs & General Counsel	no data	no data	no data
Nicole Bertsch	Senior Director & Head of Human Resources	3.2yrs	no data	no data
Maria Habel	VP, Head of Preclinical R&D and QC	11.3yrs	no data	no data
Bruce Burnett	VP & Head of Medical Affairs	no data	no data	no data
Kofi Boaten	Senior Director and Head of Supply Quality & Clinical Trial Supplies	no data	no data	no data
Peter Hurt	Senior Director and Head of Drug Safety & Pharmacovigiliance	no data	no data	no data

3.4yrs

Average Tenure

55yo

Average Age

Experienced Management: IFRX's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Niels Riedemann	Co-Founder	no data	no data	1.82% € 1.5m
Renfeng Guo	Co-Founder	no data	no data	2.99% € 2.4m
Nicolas Fulpius	Independent Chairman of the Board	17.3yrs	no data	0.79% € 641.1k
K. Reinhart	Member of Scientific Advisory Board	no data	no data	no data
P. Ward	Member of Scientific Advisory Board	no data	no data	no data
Richard Brudnick	Independent Non-Executive Director	5yrs	no data	0.085% € 68.5k
Hege Hellstrom	Non-Executive Director	1.1yrs	no data	no data
Mark Kubler	Independent Non-Executive Director	9.3yrs	no data	1.63% € 1.3m
Anthony Gibney	Independent Non-Executive Director	3yrs	no data	0.017% € 13.7k

5.0yrs

Average Tenure

52yo

Average Age

Experienced Board: IFRX's board of directors are considered experienced (5 years average tenure).

InflaRx Management

Management criteria checks 2/4

Key information

Recent management updates

InflaRx N.V., Annual General Meeting, Apr 25, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Co-Founder notifies of intention to sell stock

InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer

Recent updates

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Consensus revenue estimates fall by 13%

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

No longer forecast to breakeven

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates fall by 68%

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Consensus revenue estimates increase by 883%, EPS downgraded

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Consensus revenue estimates increase by 34%

Consensus revenue estimates increase by 34%

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx reports Q2 results

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Consensus revenue estimates fall by 31%

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Our First Look At InflaRx

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Consensus forecasts updated

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

InflaRx initiates mid-stage vilobelimab skin cancer trial

Consensus revenue estimates increase to €1.05m

Inflarx Announces Positive Topline Results for Vilobelimab from the U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

Consensus forecasts updated

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

New 90-day high: US$6.34

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

Inflarx Provides an Update on the Ongoing Development of Vilobelimab (Ifx-1), First-In-Class Anti-C5a Antibody

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate